Brisbane biotech Vaxxas secures US patent for needle-free vaccine technology

Manufacturing News

Brisbane-based clinical-stage biotechnology company Vaxxas secured a new patent from the United States patent office covering its proprietary manufacturing technology for needle-free vaccine patches, the company announced on Wednesday. The patent covers Vaxxas’ printhead system that dispenses dried vaccine formulations onto the company’s high-density microarray patch (HD-MAP), which features thousands of microscopic projections on a…

Australian company develops vaccine ‘patch’ that could replace needles

Manufacturing News

Brisbane-based biotechnology company Vaxxas published new research on Wednesday showing promising results for its needle-free vaccine delivery technology. The company’s high-density microarray patch (HD-MAP) – a small patch containing thousands of tiny projections coated with vaccine – successfully delivered a DNA-based COVID-19 vaccine in animal testing, according to research published in the science journal Heliyon.…

Innovative gel offers hope against resistant infections in trial

Manufacturing News

Recce Pharmaceuticals has announced promising outcomes from the Phase II trial of their innovative RECCE 327 Topical Gel (R327G), signaling a potential breakthrough in the fight against antibiotic-resistant infections.  This new gel is being developed to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI), offering hope where traditional treatments falter. The trial recently completed…

Recce awarded $US 2 million grant to develop burn treatment for military

Manufacturing News

Recce Pharmaceuticals has been awarded a grant of US$2 million (approximately $3 million) by the US Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP) for development of burn wound treatments. Recce, an ASX-listed company developing synthetic anti-infectives, said in a statement on Monday morning (AEST) that the grant recognised its RECCE 327 Gel (R327G)…